Compounding pharmacies are currently allowed to produce versions of GLP-1 medications like tirzepatide, despite the FDA's recent decision to remove it from the national shortage list. This situation arose after a lawsuit from the Outsourcing Facilities Association, which argues that the FDA's actions were arbitrary given ongoing shortages. As the FDA re-evaluates its stance, compounding pharmacies are advised to prepare for potential revenue losses if they can no longer operate in this capacity.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.